12 Most Promising Biotech Stocks According to Wall Street Analysts

3. Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Analyst Upside: 75.14% 

Apellis Pharmaceuticals, Inc., (NASDAQ:APLS) is a biopharmaceutical company focused on developing therapies targeting the complement system, specifically at the C3 protein level, to treat rare and serious diseases. The company generates revenue through its FDA-approved products, SYFOVRE for geographic atrophy and EMPAVELI for paroxysmal nocturnal hemoglobinuria.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) reported strong financial results for Q4 and the full year 2024, highlighting significant revenue growth. Q4 2024 revenue reached $212.5 million, up from $146.4 million in Q4 2023, while full-year revenue surged 97% to $781.4 million from $396.6 million in 2023. This growth was primarily driven by the strong sales of SYFOVRE, the first approved treatment for geographic atrophy (GA), which generated $167.8 million in Q4 and $611.9 million for the year. EMPAVELI also contributed with $23.4 million in Q4 and $98.1 million for the full year.

Despite a net loss of $36.4 million for Q4 2024 and $197.9 million for the year, Apellis Pharmaceuticals, Inc., (NASDAQ:APLS) showed significant improvement in its financial performance compared to 2023, where losses were higher. R&D expenses decreased, reflecting improved operational efficiency, and SG&A expenses remained stable. As of December 31, 2024, the company had $411.3 million in cash and cash equivalents, positioning it to continue operations until profitability.

Looking ahead, Apellis Pharmaceuticals, Inc., (NASDAQ:APLS) benefits from a first-mover advantage with SYFOVRE in the GA market, and its pipeline expansion, including potential approvals for C3G and IC-MPGN, could further boost revenues. Strategic collaborations, such as with Sobi, enhance global reach, and the company’s path to profitability is becoming clearer with strong revenue growth and controlled expenses. Most promising stocks are often those that show significant potential for growth, and Apellis is positioning itself to be one of them.